Société Cullinan Therapeutics, Inc.
Actions
CGEM
US2300311063
Recherche biotechnologique et médicale
Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
28,1 USD | +4,04% | +48,76% | +175,76% |
29/04 | Cullinan Therapeutics nomme Mary Kay Fenton au poste de directeur financier | MT |
16/04 | Transcript : Cullinan Oncology, Inc. - Special Call |
Métier
Nombre d'employés: 85
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Nadim Ahmed
CEO | Chief Executive Officer | 56 | 18/10/21 |
Jeffrey Jones
CTO | Chief Tech/Sci/R&D Officer | 53 | 28/02/22 |
Jacquelyn Sumer
CMP | Compliance Officer | 46 | 15/08/22 |
Chief Tech/Sci/R&D Officer | 57 | 01/01/18 | |
Kevin Johnston
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/22 |
Chad Messer
IRC | Investor Relations Contact | - | 01/03/22 |
Corinne Savill
PRN | Corporate Officer/Principal | 64 | 01/02/17 |
Stephen Andre
HRO | Human Resources Officer | 62 | 01/04/22 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Chairman | 71 | 01/08/17 | |
Thomas Ebeling
BRD | Director/Board Member | 65 | 01/08/17 |
Stephen Webster
BRD | Director/Board Member | 63 | 01/09/20 |
Nadim Ahmed
CEO | Chief Executive Officer | 56 | 18/10/21 |
Director/Board Member | 52 | 28/02/22 | |
David Ryan
BRD | Director/Board Member | 57 | 01/11/22 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 43 065 645 | 40 310 790 ( 93,60 %) | 0 | 93,60 % |
Coordonnées société
Secteur
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+175,76% | 1,21 Md | |
+0,67% | 42,4 Md | |
+46,90% | 40,04 Md | |
-6,20% | 28,31 Md | |
+6,55% | 24,94 Md | |
-21,66% | 18,96 Md | |
+29,96% | 12,3 Md | |
-1,57% | 11,95 Md | |
+16,03% | 11,32 Md | |
-4,80% | 11,55 Md |
- Bourse
- Actions
- Action CGEM
- Société Cullinan Therapeutics, Inc.